title: Lhermitte's sign: incidence and treatment variables influencing risk after irradiation of the cervical spinal cord.
abstract: OBJECTIVE
  Lhermitte's sign is a relatively infrequent sequela of irradiation of the cervical spinal cord. In this study, we sought to determine whether various treatment parameters influenced the likelihood of developing Lhermitte's sign.
  
  
  METHODS
  Between October 1964 and December 1987, 2901 patients with malignancies of the upper respiratory tract were treated at the University of Florida. The dose of radiation to the cervical spinal cord was calculated for those patients who had a minimum 1-year follow-up. A total of 1112 patients who received a minimum of 3000 cGy to at least 2 cm of cervical spinal cord were included in this analysis.
  
  
  RESULTS
  Forty patients (3.6%) developed Lhermitte's sign. The mean time to development of Lhermitte's sign after irradiation was 3 months, and the mean duration of symptoms was 6 months. No patient with Lhermitte's sign developed transverse myelitis. Several variables were examined in a univariate analysis, including total dose to the cervical spinal cord, length of cervical spinal cord irradiated, dose per fraction, continuous-course compared with split-course radiotherapy, and once-daily compared with twice-daily irradiation. Only two variables proved to be significant. Six (8%) of 75 patients who received > or = 5000 cGy to the cervical spinal cord developed Lhermitte's sign compared with 34 (3.3%) of 1037 patients who received < 5000 cGy (p = .04). For patients treated with once-daily fractionation, 28 (3.4%) of 821 patients who received < 200 cGy per fraction developed Lhermitte's sign compared with 6 (10%) of 58 patients who received > or = 200 cGy (p = .02).
  
  
  CONCLUSIONS
  An increased risk of developing Lhermitte's sign was demonstrated for patients who received either > or = 200 cGy per fraction (one fraction per day) or > or = 5000 cGy total dose to the cervical spinal cord.
authors.affiliation: Department of Radiation Oncology, University of Florida, College of Medicine, Gainesville 32610-0385.
authors.forename: D A
authors.initials: DA
authors.lastname: Fein
authors.forename: R B
authors.initials: RB
authors.lastname: Marcus
authors.forename: J T
authors.initials: JT
authors.lastname: Parsons
authors.forename: W M
authors.initials: WM
authors.lastname: Mendenhall
authors.forename: R R
authors.initials: RR
authors.lastname: Million
mesh_terms: D002277:Carcinoma / Q000532:radiotherapy; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000532:radiotherapy*; D008223:Lymphoma / Q000532:radiotherapy; D011832:Radiation Injuries / Q000453:epidemiology* / Q000209:etiology; D011878:Radiotherapy / Q000009:adverse effects* / Q000379:methods; D011879:Radiotherapy Dosage; D012142:Respiratory Tract Neoplasms / Q000532:radiotherapy*; D012189:Retrospective Studies; D012307:Risk Factors; D012509:Sarcoma / Q000532:radiotherapy; D013116:Spinal Cord / Q000528:radiation effects*; D013997:Time Factors